29 March 2022 - The Australian Government is investing in a stronger health system as part of our plan for a stronger future through a record $132 billion in 2022–23, increasing to $140 billion in 2025–26, with a total commitment of $537 billion over the next four years.

New listings from April 2022:

• Trikafta, the combination product of elexacaftor/tezacaftor/ivacaftor and ivacaftor for the treatment of cystic fibrosis, helping an average 1,900 Australians reduce their out of pocket costs by around $250,000 a year.

New listings from May 2022:

• Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy in children less than nine-months old with type 1 SMA or pre-symptomatic patients with 1-2 copies of the SMN2 gene, which will save families of an average of 20 patients each year more than $2.5 million per treatment.
• Trodelvy (sacituzumab govitecan) for the treatment of triple negative breast cancer, which will save an average of 580 patients each year $80,000 per course of treatment.
• Ofev (nintedanib) for use in the treatment of progressive fibrosing interstitial lung disease, which will save more than 1,400 Australians around $40,000 a year.

Read Minister of Health press release